ARTICLE | Deals
Zurzuvae denial turns up pressure on Biogen’s execution of Skyclarys
Making the Reata deal profitable will require commercial success outside the U.S.
August 8, 2023 1:27 AM UTC
With the commercial prospects of its depression drug Zurzuvae dimmed, pressure is mounting for Biogen to successfully execute on its acquisition of Reata, and possibly continue building through more deals.
There are reasons to be optimistic that Biogen Inc. (NASDAQ:BIIB) will be able to deliver a strong U.S. launch of the Friedreich ataxia drug for which it is buying Reata Pharmaceuticals Inc. (NASDAQ:RETA). ...